Date: 09.05.2012

“junk” dna not so junky

Junk DNA

From the New York Times:

The human genome is packed with at least four million gene switches that reside in bits of DNA that once were dismissed as “junk” but that turn out to play critical roles in controlling how cells, organs and other tissues behave. The discovery, considered a major medical and scientific breakthrough, has enormous implications for human health because many complex diseases appear to be caused by tiny changes in hundreds of gene switches.

The findings are the fruit of an immense federal project, involving 440 scientists from 32 labs around the world. As they delved into the “junk” — parts of the DNA that are not actual genes containing instructions for proteins — they discovered it is not junk at all. At least 80 percent of it is active and needed.

The result is an annotated road map of much of this DNA, noting what it is doing and how. It includes the system of switches that, acting like dimmer switches for lights, control which genes are used in a cell and when they are used, and determine, for instance, whether a cell becomes a liver cell or a neuron.

More here.

new adrogen blocking drug approved for prostate cancer

From Elie Dolgin of Nature magazine covers the news:

Men with advanced prostate cancer now have another treatment option, thanks to the approval today by the US Food and Drug Administration (FDA) of a pill that blocks androgen-receptor signaling and prolongs patient survival.

“To see activity in a post-hormone treated, post-chemotherapy treated prostate cancer population with a drug that doesn’t have myelosuppression [a decrease in blood cell production] and does has a very favorable safety profile is extremely exciting,” says Howard Scher, a prostate cancer specialist at the Memorial Sloan-KetteringCancer Center in New York. “My patient who got the drug in July 2007 is still on it. I have chills actually. It’s pretty amazing.”

The newly approved agent—Xtandi (enzalutamide), developed by San Francisco’s Medivation and Japan’s Astellas Pharma—works by plugging up the receptors that bind androgens, including testosterone, to prevent those male hormones from fueling the growth of prostate cancer cells. In a phase 3 clinical trial involving around 1,200 men with prostate cancer that had spread despite prior chemo- and hormone-therapy, an international team led by Scher found that participants taking Xtandi lived a median of 18.4 months, compared to 13.6 months for those who received a placebo. The drug also significantly lowered levels of prostate-specific antigen and boosted the time of progression-free survival, with only minimal side effects of fatigue, diarrhea and rare seizures. The results were reported earlier this month in the New England Journal of Medicine.

Read the complete coverage here.

invertebrates face threat of extinction

One in five of the world’s invertebrate species are threatened with extinction, according to the latest report from the Zoological Society of London (ZSL).

…the greatest threat is to freshwater invertebrates, including crabs and snails, followed by terrestrial and marine invertebrates. More mobile animals, such as butterflies and dragonflies, tended to have the least risk of extinction.

The report estimates that 34% of freshwater invertebrates could be under threat, including more than half of the world’s freshwater snails and slugs. In the southeastern United States, which is a freshwater diversity hotspot, almost 40% of molluscs and crayfish could be wiped out owing to the effects of dams and pollution. In the oceans, almost one-third of reef-building corals are endangered largely because of climate change, which causes coral bleaching and ocean acidification.

Overall, habitat loss, pollution and invasive species represented the biggest threats to invertebrate diversity around the world. The proportion of species at risk (one-fifth) is similar to findings in vertebrates and plants. The report will be formally presented on 7 September at the World Conservation Congress in Jeju, South Korea, where conservationists, scientists and government leaders will meet to discuss conservation and development issues.

More from Brendan Borrell at Scientific American.

//eejersenset.net/4/4535925